Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Sectors
Healthcare
Life Sciences
First Invested
2020
Growth
Company Status
IPO/Public
NASDAQ: GERN
Associated Team
Lulu Xu
Paul Walker